Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High‐Intensity Focused Ultrasound ( HIFU ) Failure
Journal of Medical Imaging and Radiation Oncology · 2025
DOI: 10.1111/1754-9485.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2025. Verfasst von Atsuto Katano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Salvage Therapy, Prostatic Neoplasms, Neoplasm Recurrence, Local, High-Intensity Focused Ultrasound Ablation. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Prostate cancer is a prevalent malignancy with rising incidence rates globally. High‐intensity focused ultrasound (HIFU) is a promising, minimally invasive treatment for localised prostate cancer. However, recurrence following HIFU, indicated by rising PSA levels or imaging‐confirmed local recurrence, remains a concern. Salvage radiotherapy is a potential treatment for recurrent prostate cancer post‐HIFU, but evidence on its efficacy and safety is limited.
Method
This retrospective study evaluated eight patients with localised prostate cancer who underwent salvage radiotherapy following HIFU failure. Salvage treatment consisted of external beam radiation therapy (EBRT), delivered either as conventional fractionation (76 Gy in 38 daily fractions) or stereotactic ablative radiotherapy (36.25–40 Gy in five alternate‐day fractions). Outcomes assessed included prostate‐specific antigen (PSA) response, biochemical progression‐free survival (bPFS), overall survival (OS) and treatment‐related toxicity profiles.
Results
All eight patients experienced a significant decline in PSA levels, with no biochemical failures observed during a median follow‐up of 72.4 months. The 5‐year biochemical failure‐free survival and overall survival rates were 100%. Among the eight patients, 6 (75%) had Grade 2 or lower genitourinary toxicity, and 5 (62.5%) had Grade 2 or lower gastrointestinal toxicity, with no Grade 3 or higher adverse events.
Discussion
Salvage EBRT after HIFU failure provides durable disease control with manageable side effects. Further research with larger cohorts is needed to refine treatment strategies for recurrent prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
ORCID-Profile: Atsuto Katano, Masanari Minamitani, Hideomi Yamashita
Zitieren
APA
Katano, A., Minamitani, M., Sawayanagi, S., & Yamashita, H. (2025). Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High‐Intensity Focused Ultrasound ( HIFU ) Failure. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.70009
Vancouver
Katano A, Minamitani M, Sawayanagi S, Yamashita H. Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High‐Intensity Focused Ultrasound ( HIFU ) Failure. Journal of Medical Imaging and Radiation Oncology. 2025. doi:10.1111/1754-9485.70009
BibTeX
@article{Katano2025,
author = {Katano, Atsuto and Minamitani, Masanari and Sawayanagi, Subaru and Yamashita, Hideomi},
title = {Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High‐Intensity Focused Ultrasound ( HIFU ) Failure},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2025},
doi = {10.1111/1754-9485.70009}
}
EUVIMED